Edwards Lifesciences Announces Strategic Investments


March 11, 2019—Edwards Lifesciences Corporation announced strategic transactions involving companies with structural heart disease technologies: Corvia Medical, Inc. and Mitralign, Inc.

Edwards invested $35 million in an exclusive right to acquire Corvia Medical, which developed a transcatheter device designed to treat heart failure with preserved or midrange ejection fraction. The company's interatrial shunt device is designed to provide continuous and dynamic decompression of the left atrium, which may reduce symptoms and slow the progression of heart failure. The therapy has received CE Mark approval in Europe. In the United States, it is being studied as part of an FDA pivotal clinical trial.

Edwards acquired certain assets of Mitralign, including intellectual property and associated clinical and regulatory experience. Mitralign is a developer of an investigational transcatheter annuloplasty system designed to treat functional mitral and tricuspid regurgitation.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.